View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 21, 2020

Adapting Clinical Trials to a Post COVID-19 World

By Katie Wong

Low patient accrual has historically been the primary cause of trial delays, suspensions, or terminations. This highlights the significant challenges in the recruitment of clinical trial subjects in a pre-pandemic world.

It is therefore unsurprising that during the coronavirus disease 2019 (COVID-19) pandemic, an excess of 500 companies have announced that they have delayed initiation, suspended recruitment, or terminated clinical trials. When these trials resume, it is highly probable that potential trial subjects will have a heightened sense of anxiety regarding COVID-19 and therefore may have reservations about participating in clinical trials.

Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena